DNDN Stock Shoots up on Drug Trial. Dendreon.

Dendreon announces interim data from Phase 3 PROVENGE IMPACT trial; IDMC observed no safety concerns and recommended that the study continue Co announces that it has completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial designed to assess the safety and efficacy of the investigational active cellular immunotherapy PROVENGE (sipuleucel-T) in men with metastatic androgen-independent prostate cancer.






Home
RSS Feed
Email Subscribe